Hansa Biopharma: Our initial Q4 take - Redeye
Hansa's Q4 is slightly below our and the market's sales expectations and slightly better in terms of OPEX and operating cash flow. Hansa has probably delivered Idefirix to seven patients vs our expected eight patients. Some transplant centers can be expected to be ready for multiple patient treatment later in 2023. The trend of increasing partner slaes contribution is also positive. We can expect a 2023 with a gradual contribution from the early Idefirix launch together with significant pipeline progress for several projects. We expect a neutral share price reaction based on Hansa’s Q4 result and the 2023 outlook.
Länk till analysen i sin helhet: https://www.redeye.se/research/873207/hansa-biopharma-our-initial-q4-take?utm_source=finwire&utm_medium=RSS